Zidas Lifesains said on Friday that it had received approval from US health regulators for marketing generic drug for the treatment of multiple sclerosis.
Virat Kohli Test Retirement: Will Virat Kohli retire from Test cricket?
The company has received approval from the US Food and Drug Administration (USFDA) for Glatymar Acetate injection, 20 mg/ml and 40 mg/mL, single dose prefilled syringe. The company’s product is the generic version of Copaxone, indicated to the treatment of recurrent forms of multiple sclerosis (MS). Zidas said that this product developed in collaboration with Kemi SPA will be made entirely in Europe. Zidas Lifesains MD Sharvil Patel said that this approval reflects Zidas’s leadership in bringing complex, differentiated generic drugs to the market and reiterates our commitment to providing a wide range of treatment options for patients. According to IQVIA MAT data, the annual sales of the Glatymar acetate injection in the US market were US $ 719 million. Zidas Lifesains shares rose 0.48% to Rs 1,150. Its business took place at Rs 876 per share.
